**Name of journal:** *World Journal of Gastrointestinal Oncology*

**ESPS Manuscript NO: 5665**

**Columns: REVIEW**

**Antidepressant fluoxetine and its potential against colon tumors**

Stopper H *et al*. Fluoxetine and colon cancer

Helga Stopper, Sergio Britto Garcia, Ana Maria Waaga-Gasser, Vinicius Kannen

**Helga Stopper, Vinicius Kannen,** Department of Toxicology, University of Wuerzburg, D-97078 Wurzburg, Germany

**Sergio Britto Garcia,**Department of Pathology, Medical School of Ribeirão Preto, University of São Paulo, Ribeirão Preto, SP 14040-902, Brazil

**Ana Maria Waaga-Gasser,** Department of Surgery I, Molecular Oncology and Immunology, University of Wuerzburg, D-97078 Wuerzburg, Germany

**Author contributions:** StoppeH and Garcia SB contributed with unpublished data and discussions; Waaga-Gasser Vinicius K conceived and wrote this manuscript.

**Supported by** German Academic Exchange Service (DAAD), National Council for Scientific and Technological Development (CNPQ); and Foundation for Research Support of the State of São Paulo (FAPESP)

**Correspondence to: Vinicius Kannen, PhD,** Department of Toxicology, University of Wuerzburg, Versbacher Strasse 9, D-97078 Wuerzburg, Germany. vinicius.cardoso@uni-wuerzburg.de

**Telephone:** +49-931-86133 **Fax:** +49-931-86133

**Received:** September 20, 2013 **Revised:** November 9, 2013

**Accepted:** December 9, 2013

**Published online:**

**Abstract**

Colon cancer is one of the most common tumors worldwide with increasing incidence in developing countries. Patients treated with fluoxetine (FLX) have a reduced incidence of colon cancer, although there still remains great controversy about the nature of its effects. Here we explore the last achievements related to FLX treatment and colon cancer. Moreover, we discuss new ideas about the mechanisms of the effects of FLX treatment in colon cancer. This leads to the hypothesis of FLX arresting colon tumor cells at the at G1 cell-cyle phase through a control of the tumor-related energy generation machinery. We believe that the potential of FLX to act against tumor metabolism warrants further investigation.

©2013 Baishideng Publishing Group Co., Limited. All rights reserved.

**Key words:** Fluoxetine; Colon cancer; Cancer therapy; Tumor metabolism

**Core tip:** It is currently thought that aerobic glycolysis is key for understanding cell survival in the hostile tumor microenvironment. Then, the antidepressant fluoxetine has been shown to reduce colon tumor growth in animals and colon cancer incidence in humans. Here, we explore new perspectives of fluoxetine reducing the development of colon tumors through a blockage in tumor metabolism. This perspective review is based on our current unpublished experimental dataset which show fluoxetine as a potential co-chemotherapeutic agent for colon cancer therapy.

Stopper H, Garcia SB, Waaga-Gasser AM, Kannen V. Antidepressant fluoxetine and its potential against colon tumors

**Available from:**

**DOI:**

**INTRODUCTION**

Colon cancer is one of the most common human malignancies worldwide, and much effort has been applied to understand its development. The discovery of new therapeutical strategies or potential co-therapeutical agents against it might reduce the suffering of millions of people. A growing body of evidence suggests that the use of fluoxetine (FLX), an antidepressant belonging to the selective serotonin reuptake inhibitors (SSRIs), may be related to a reduced colon cancer incidence. However, its activity is not completely understood and potential new mechanisms might be unknown until now.

Here, we discuss our recent published and unpublished data regarding the activity of FLX against colon cancer. This review takes a fresh view on the material, mainly of how FLX acts to block malignant metabolism reducing colon tumors.

## COLON CANCER

The American Cancer Society estimates the number of new cases and expected deaths for cancer in the United States every year[[1](#_ENREF_1)]. About 1.5 million cases and 569490 deaths of cancer were expected in 2010. This ranked colon cancer as the third most common cancer in the United States, with almost 50000 deaths peryear[[1](#_ENREF_1),[2](#_ENREF_2)]. In this year, it is expected that more than 143460 patients will be diagnosed newly with colon cancer in the United States[[3](#_ENREF_3)]. Although survival has increased during the 5 years after diagnosis[[2](#_ENREF_2)], a 60% increase for new cancer diagnosed cases is projected for developing countries until 2030[[4](#_ENREF_4)]. This highlights colon cancer as one of the major human malignancies worldwide, and a great challenge for cancer therapy[[5-7](#_ENREF_5)].

***Adenoma-adenocarcinoma sequence model***

The adenoma-adenocarcinoma sequence model is the most well-known and accepted hypothesis for the development of colon cancer[[8](#_ENREF_8)]. It is thought that a sequence of mutations of the epithelial stem cell niche induces the development of colon tumors through different stages, such as initiation, promotion and progression[[8](#_ENREF_8)]. Initiation is known as an irreversible step, where mutations in one or two gatekeeper genes occur in a single-cryptal stem cell. This will then disrupt cell proliferation, leading to the expansion of malignant clones, a process termed promotion[[9](#_ENREF_9),[10](#_ENREF_10)]. Mutations are thought to derive from cell exposure to carcinogenic compounds which directly attack the DNA or lead to increased oxidative stress with the generation of reactive oxygen species (ROS), which would then attack the DNA basis inducing mutations[[11](#_ENREF_11),[12](#_ENREF_12)]. Clever’s research group has elegantly generated *Lgr5-EGFP-IRES-creERT2/Apcflox/flox* mice, which have a stem-cell-specific knockin reporter for tamoxifen-inducible loss of the adenomatous polyposis coli (APC) sequence, and found that this genetic deletion in epithelial stem cells lead to their transformation within days, which was due to β-catenin accumulation[[13](#_ENREF_13)]. This further supports the idea that a monoclonal propagation of acquired stem-cell mutations occurs during the initial steps of colon carcinogenesis[[9](#_ENREF_9)]. The manifestation of mutations in colon epithelia seems to be closely related to hyperproliferation[[13-15](#_ENREF_13)]. In fact, mutations in the *APC* gene sequence at cryptal stem cell niches activate hyperproliferation due to an increase in β-catenin transcriptional activity which blocks p53 activity[[15-17](#_ENREF_15)].

***Sub-epithelial cells and their role in carcinogenesis***

The cancer-enhancing activity of the microenvironment has been a matter of discussion, since recent reports showed that disrupting key genetic sequences in stromal cells abrogates epithelial homeostasis, which then induces tumors[[18-20](#_ENREF_18)]. An elegant report has specifically shown that epithelial tumors have arisen in forestomach after disrupting the transforming growth factor-β (TGF-β) signaling within the sub-epithelias compartment[[21](#_ENREF_21)]. Previous studies had already shown that the sub-epithelial TGF-β signaling has tumor promoting potential on epithelial cells, due to its control over proliferation[[22](#_ENREF_22),[23](#_ENREF_23)]. Nevertheless, under inflammatory conditions sub-epithelial cells seem to be able to transform epithelial progenitor cells towards malignancy[[20](#_ENREF_20)]. These ideas have actually been applied to colon carcinogenesis confirming the malignant participation of sub-epithelial cells in the development and manifestation of colon tumors[[20](#_ENREF_20),[24](#_ENREF_24),[25](#_ENREF_25)].

## TUMOR METABOLISM

Hyperproliferation enables the clonal expansion of mutated cells, which further drives tumor growth[[14](#_ENREF_14),[15](#_ENREF_15),[17](#_ENREF_17),[26-29](#_ENREF_26)]. For this, tumor cells require: high and fast adenosine-5’-ATP generation; a tightened maintenance of the cell redox status to overcome the stressful tumor microenvironment; and, enhanced biosynthesis of macromolecules. Basically, tumor cells shift their energy generation machinery from oxidative phosphorylation to an aerobic-glycolytic metabolism[[30](#_ENREF_30),[31](#_ENREF_31)]. This allows tumor cells to keep a high ATP generation and at the same time to avoid the negative feedback regulation from overusing glycolysis, which would otherwise activate metabolic and cell-cycle inhibitors, such as p53[[30](#_ENREF_30)]. This was extensively discussed by Cairns *et al*[[31](#_ENREF_31)]. Specifically, glycolysis-related mechanisms enhance the synthesis of nucleotides and DNA repair[[30](#_ENREF_30),[31](#_ENREF_31)]. However, high proliferation enlarges the distance between cells and microvessels, which reduces the oxygen and nutrient supplies to the cells and creates a hypoxic microenvironment. While hypoxia generally promotes the expression of growth factors inducing neovascularization, hypoxic areas in tumors may persist due to the chaotic and malformed structures of tumoral vessels and microvessels[[14](#_ENREF_14),[32-34](#_ENREF_32)].

Moreover, hypoxic tumor cells are known to use glycolysis in order to increase energy generation (Figure 1). This requires an over-activation of glucose transporters (*i.e.*, GLUT1), lactate transporters (*i.e.*, MCT4) and lactate dehydrogenase A (LDH-A) through the hypoxia-inducible factor 1 (HIF-1) transcriptional activity. By inhibiting the degradation of HIF-1, a transcription factor which upregulates the glycolysis-related molecular activities, tumor cells increase the conversion of pyruvate to lactate[[32](#_ENREF_32),[35](#_ENREF_35)]. Because tumor cells would then suffer from the hypoxia-induced and glycolysis-related acidosis, they alkalinize their intracellular pH(ipH) on their way to survival and proliferation. This is achieved via hyperactivation of HIF-1 activity, which enhances the hydration of carbon dioxide (CO2) to bicarbonate by the catalytic activity of carbonic anhydrase (CA) IX and XII enzymes and promotes the activity of MCT-4 to extrude lactate and H+ ions, both supporting an intracellular pH (ipH) alkalinization[[32](#_ENREF_32),[36](#_ENREF_36)]. Overall, tumor cells undergo deep metabolic changes on their way to survival in the stressful tumoral microenvironment[[31](#_ENREF_31)].

## ANTIDEPRESSANT FLX MODULATES OXIDATIVE STRESS

FLX was first reported by a research group from the Eli Lilly Company in 1974, as a selective serotonin reuptake inhibitor (SSRI)[[37](#_ENREF_37)]. In 1978, the United States Food and Drug Administration approved FLX for the treatment of patients with depression, anxiety and insomnia; this medication became known worldwide as Prozac[[38](#_ENREF_38),[39](#_ENREF_39)]. This antidepressant exhibits higher safety and fewer side effects than other groups of antidepressants[[38-41](#_ENREF_38)]. FLX was characterized as a lipophilic weak base, which when administered orally experiences a direct contact with epithelial cells in the intestines. In these epithelial cells it induces an increase in serotonin (5-HT) levels by blocking L-monoamine oxidase and serotonin reuptake transporters[[41-43](#_ENREF_41)].

On the other hand, FLX has been shown to interfere with the oxidative stress (OS) machinery in experimental models and humans[[44-55](#_ENREF_44)]. Treatment with FLX was found, in stressed rats, to reduce malondialdehyde (MDA) and carbonyl levels, whilst it enhanced superoxide dismutase (SOD), catalase, glutathione S-transferase, glutathione reductase (GR) and glutathione contents[[45](#_ENREF_45),[46](#_ENREF_46)]. Similar findings were reported by another research group[[48](#_ENREF_48)]. Then, this compound showed neuroprotective effects decreasing the translocation of p67 protein and ROS generation (by suppressing the activation of NADPH oxidase, and inducible nitric oxide synthase) in rats exposed to lipopolysaccharide)[[47](#_ENREF_47)]. In depressive patients, FLX was found to decrease serum MDA, SOD, and ascorbic acid levels[[44](#_ENREF_44)].

## FLX AND TUMORS

Tutton and Barkla first revealed the anticancer potential of FLX against colon tumors[[56](#_ENREF_56)]. However, in 1992, Brandes and colleagues reported a 40% increase of the numbers of mammary fibrosarcomas among mice treated with FLX for 5 d, which was followed by findings of a 95% enhancement in breast cancer incidence after 15 wk[[57](#_ENREF_57)]. Opposite to that, Volpe *et al*[[58](#_ENREF_58)] showed that treating human and murine breast tumor cell lines with FLX *in vitro* did not stimulate tumor cell proliferation, DNA synthesis, or colony formation. Jia and colleagues reported that FLX did not enhance the growth of pancreatic tumors[[59](#_ENREF_59)]. Moreover, this treatment was further found to reduce lymphoma growth modulating the T-cell-mediated immunity reaction through a 5-HT-dependent activity[[40](#_ENREF_40)].

In patients, FLX treatment was reported to reduce the risk of colon cancer to almost 50%[[60](#_ENREF_60)]. Chubak *et al*[[61](#_ENREF_61)] also observed that FLX reduced the of colon cancer in humans, while one meta-analysis study suggested that FLX does not act on colon cancer[[62](#_ENREF_62)]. Studies with animal models support the idea of FLX reducing colon cancer incidence in different animal models, such as carcinogen induced preneoplastic lesions and tumors in rats and mice, and xenograft-tumors in immunosuppressed rats[[38](#_ENREF_38),[63-65](#_ENREF_63)]. These studies have mainly being focused on the antiproliferative effects of FLX treatment in colon tumorigenesis[[38](#_ENREF_38),[63-65](#_ENREF_63)]. In cell culture models, FLX was reported to not only inhibit multidrug resistance and increase the intracellular doxorubicin concentration[[66](#_ENREF_66)], but also to induce a further nuclear distribution of this chemotherapeutic drug[[67](#_ENREF_67)].

***FLX reduces preneoplastic lesions acting on colonic microenvironment***

We have reported that FLX treatment counteracted the carcinogen-induced dysplasia in two different experimental colon cancer models[[64](#_ENREF_64),[65](#_ENREF_65)]. Our first report revealed FLX as a chemopreventive compound against colonic dysplasia, since treatment with FLX was started before the treatment with the carcinogen[[65](#_ENREF_65)]. We then reported that FLX could also reduce pre-existent colon preneoplastic lesions[[64](#_ENREF_64)]. Our findings suggested that FLX takes the carcinogen-induced preneoplastic changes under control by reducing epithelial proliferation[[38](#_ENREF_38),[56](#_ENREF_56),[60](#_ENREF_60),[61](#_ENREF_61),[64](#_ENREF_64),[65](#_ENREF_65)].

Besides the fact that FLX treatment reduced dysplasia and preneoplastic angiogenesis decreasing the epithelial and sub-epithelial proliferation[[64](#_ENREF_64),[65](#_ENREF_65)], our unpublished dataset further suggests that by suppressing the NF-κB nuclear activity, through increased expression of cytoplasmic NF-κB-inhibitor IκB-α and IκB-β proteins, FLX reduced *c-Myc* expression and then stromal proliferation (Figures 2 and 3). As we will discuss next, FLX treatment seems to take preneoplastic angiogenesis under control by reducing the proliferation of sub-epithelial cells (Figure 4). Indeed, NF-κB-transcriptional activity was reported to induce the transformation of sub-epithelial cells from normal to reactive phenotypes, enhancing the expression of pro-inflammatory molecules and periendothelial cell numbers[[68](#_ENREF_68),[69](#_ENREF_69)]. Koh *et al*[[38](#_ENREF_38)]reported that FLX inhibited NF-κB signaling in colonic epithelial tumor cells. Inhibition of the NF-κB-transcriptional activity actually yields reduced expression of its downstream genes c*-Myc* and VEGF, which blocks the proliferation of colon cancer cells[[70](#_ENREF_70),[71](#_ENREF_71)].

The activity of FLX on the colonic preneoplastic microenvironment further includes the question whether this treatment could directly act upon angiogenesis-related cell phenotypes[[64](#_ENREF_64),[65](#_ENREF_65)]. We have demonstrated that the anti-angiogenic potential of FLX could be related to its control over the differentiation and further transition of endothelial cells through different angiogenesis-related stem cell markers in colon preneoplastic lesions (Figure 4)[[64](#_ENREF_64)]. This idea was abetted by the discovery of a small subset of stromal spindle cells expressing CD133 and CD34 in angiofibromas, which suggests tumors promoting sub-epithelial resident cells to transit towards endothelial cell phenotypes[[72](#_ENREF_72)]. Endothelial progenitor cells were then shown to lose, in a process related to high proliferation[[73](#_ENREF_73)], the expression of CD133 during their differentiation into vascular cells, while the expression of CD34 was increased[[74-76](#_ENREF_74)]. Considering that CD31-positive cells have been designated as a mature endothelial lineage promoting microvessels[[77](#_ENREF_77)], vascular smooth muscle cells were found to increase the expression of CD31 during their differentiation process, whilst a simultaneous decrease of CD133 and CD34 progenitor markers was previously observed[[78](#_ENREF_78),[79](#_ENREF_79)].

## FLX TAKES ENERGY GENERATION UNDER CONTROL TO REDUCE MALIGNANT EXPANSION

Here, we should pull a few points together about malignancy, ROS production, and energy generations, as: (1) unbalancing the machinery for energy generation induces ROS production; (2) ROS production is one of the main known events inducing DNA damage and mutation; (3) ROS generation promotes genetic mutations leading to the manifestation of preneoplastic lesions; (4) tumor cells undergo deep metabolic changes to survive and promote malignant expansion; (5) tumors enhance ROS production to promote growth through malignant molecular signaling; and (6) malignant metabolism seems to be the Achilles’ heels in tumors. These few remarks give us the notion that metabolism, or energy generation, is a key for malignant transformation, tumor manifestation, and growth, as well as a valuable tool for anticancer therapy[[35](#_ENREF_35),[80-82](#_ENREF_80)].

As a lipophilic weak base[[42](#_ENREF_42)] FLX quickly diffuses through multiple body-sites[[83](#_ENREF_83)]. We have already demonstrated that FLX treatment arrested colon tumor cells within the G0/G1 cell-cycle phase without inducing DNA damage[[64](#_ENREF_64)]. Then, FLX was shown to reduce ROS generation reversing the melanoma-induced tissue oxidation in mice[[50](#_ENREF_50)]. In brain tissue of tumor-bearing mice FLX treatment further reduced oxidative stress enhancing the SOD activity[[49](#_ENREF_49)]. Actually, FLX was twice reported to stimulate Ca2+ flux reducing the B-cell lymphoma 2 (bcl-2) expression and mitochondrial membrane potential (ΔΨm), which induced DNA fragmentation and apoptosis in Burkit lymphoma cells[[52](#_ENREF_52),[53](#_ENREF_53)]. Another lipophilic weak base ([Z]-5-methyl-2-[2-(1-naphthyl) ethenyl]-4-piperidinopyridine [AU-1421]) was also reported to uncouple mitochondrial oxidative phosphorylation dissipating the proton motive force during its energized state, which inhibited ATP synthesis[[84](#_ENREF_84)]. It is known that lipophilic weak bases, such as FLX, reduce ΔΨm (or extra- and intra-mitochondrial motions of H+ atoms generating positive charges in the mitochondrial membrane) in their energized or protonated state, which reduces mitochondrial respiratory rate and energy generation[[84-86](#_ENREF_84)]. FLX was also found to induce ROS generation in human ovarian cancer cell lines, which induced apoptosis through mitochondrial bcl-2-associated X protein, cytochrome c release, caspase-3 activation and p53 expression levels, whilst this treatment further reduced ΔΨm, BH3 interacting-domain death agonist and bcl-2 levels[[54](#_ENREF_54)]. Similar findings were reported in human neuroblastomas[[55](#_ENREF_55)].

Comparing those reports that describe how FLX modulates tumor metabolism[[49](#_ENREF_49),[50](#_ENREF_50),[52-55](#_ENREF_52)] with others describing its activity against tumor growth[[40](#_ENREF_40),[58](#_ENREF_58),[87-92](#_ENREF_87)], it becomes clear that FLX blocks tumor cell proliferation by impairing the malignant energy generation. The anti-tumor proliferative effects of FLX[[40](#_ENREF_40),[56](#_ENREF_56),[92](#_ENREF_92),[93](#_ENREF_93)] have been related to different causes, such as, delays in cell-cycle progression by inhibiting DNA synthesis and also to a possible binding directly to DNA via groove mode and high attraction force[[58](#_ENREF_58),[87-90](#_ENREF_87),[94](#_ENREF_94)]. On a molecular level, FLX was shown to arrest breast tumor cells at G0/G1 phase by disrupting skp2-CKS1 assembly, which is required to enable cell cycle progression[[91](#_ENREF_91)]. Recent reports have been supporting the idea of FLX acting against tumor proliferating cells by reducing *c-Myc* and cyclins (D1, D3, E, B and A), whereas cell-cycle checkpoints (p15, p16, p21, p27 and p53) were enhanced[[40](#_ENREF_40), [91](#_ENREF_91), [92](#_ENREF_92)].

***Perspectives in FLX treatment acting against colon cancer***

The application of FLX for tumor patients has so far been limited to its use as an antidepressant, but it might provide much more benefit, potentially making it an interesting co-chemotherapeutic agent. FLX treatment seems to block tumor growth by breaking the malignant metabolism down[[49](#_ENREF_49),[52-55](#_ENREF_52)]. While the pieces for this puzzle are slowly being pulled together, there are already several reports which have given the ground ideas for following investigations[[38-40](#_ENREF_38),[49](#_ENREF_49),[50](#_ENREF_50),[52-56](#_ENREF_52),[58](#_ENREF_58),[60](#_ENREF_60),[61](#_ENREF_61),[64-67](#_ENREF_64),[87-92](#_ENREF_87),[95](#_ENREF_95)]. Besides the specific idea of FLX acting against the tumor metabolism, there is an open question regarding the effects of FLX treatment against the “reverse Warburg effect”. Pavlides *et al*[[96](#_ENREF_96)]have suggested the idea of a reverse Warburg effect taking place in tumors; this idea argues that epithelial cancer cells induce the sub-epithelial cells to undergo aerobic-glycolysis and secrete lactate and pyruvate, which malignant cells would take up to enhance their tricarboxylic acid cycle *in via* not only to generate more energy through mitochondrial phosphorylation, but further increase redox mechanisms which turns to corroborate with tumor cell survival and proliferation[[30](#_ENREF_30),[31](#_ENREF_31),[82](#_ENREF_82)]. Schulze and colleagues have extensively reviewed this topic[[30](#_ENREF_30),[82](#_ENREF_82)]. Such a mechanism would efficiently ensure enough energy production for malignant cells within the hostile tumor environment, allowing not only high proliferative rates, but the enhancement of malignant angiogenesis[[97-101](#_ENREF_97)]. These authors have further shown that enhancing the sub-epithelial NF-κB signaling is closely associated with “reverse Warburg effect” in tumors[[96](#_ENREF_96)].

Our findings, that FLX treatment reduced the nuclear detection of NF-κB protein among preneoplastic sub-epithelial cells (as related to reduced angiogenesis due to fewer sub-epithelial cellular proliferation[[64](#_ENREF_64), [65](#_ENREF_65)]), lead towards the idea of FLX treatment having similar effects on sub-epithelial cells which surround epithelial cells in colon tumors. Figure 5 illustrates that malignant microvessels show high-cytochrome c oxidase activity in colon-xenograft tumors. Moreover, our new experiments (unpublished dataset) argue that FLX treatment, in different colon tumor models, takes the malignant metabolism-related energy generation in epithelial cells under control to shrink tumors. We strongly believe that FLX counteracts aerobic glycolysis reducing the activity of lactate transporters that inhibits oxidative phosphorylation due to increased intracellular levels of lactate. This might bring down the ipH values blocking the tumor energy generation machinery. After having this hypothesis challenged in experimental models and by different research groups, we could think of clinical trials for FLX as co-chemotherapeutic agent in colon cancer patients. Because of low costs of FLX this would also be transferable to developing countries with their tightly limited budget for cancer therapy.

**CONCLUSION**

To summarize, research data concerning the activity of FLX treatment against tumor metabolism are still very limited, but exciting enough to warrant new investigations. The fact that FLX was designed as an antidepressant but was further found to act against tumors already highlights that new drugs can be developed from it. Additionally, cancer therapy lacks in alternative strategies to overcome chemoresistance. In many cases chemoresistance is closely associated with tumor metabolism. It seems reasonable to suggest that treatments disrupting metabolic events, as might be possible with FLX, could effectively not only reduce chemoresistance but also malignant angiogenesis. Whether these new perspectives for FLX treatment will be applicable for colon cancer patients are a matter of time, discussion, and deeper research efforts. We strongly suggest that FLX is a promising target for further studies in cancer research.

**REFERENCES**

1 **Jemal A**, Siegel R, Xu J, Ward E. Cancer statistics, 2010. *CA Cancer J Clin* 2010; **60**: 277-300 [PMID: 20610543 DOI: 10.3322/caac.20073]

2 **Lea A**, Allingham-Hawkins D, Levine S. BRAF p.Val600Glu (V600E) Testing for Assessment of Treatment Options in Metastatic Colorectal Cancer. *PLoS Curr* 2010; **2**: RRN1187 [PMID: 20972475 DOI: 10.1371/currents.RRN1187]

3 **Siegel R**, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T, Cooper D, Gansler T, Lerro C, Fedewa S, Lin C, Leach C, Cannady RS, Cho H, Scoppa S, Hachey M, Kirch R, Jemal A, Ward E. Cancer treatment and survivorship statistics, 2012. *CA Cancer J Clin* 2012; **62**: 220-241 [PMID: 22700443 DOI: 10.3322/caac.21149]

4 **Jemal A**, Center MM, DeSantis C, Ward EM. Global patterns of cancer incidence and mortality rates and trends. *Cancer Epidemiol Biomarkers Prev* 2010; **19**: 1893-1907 [PMID: 20647400 DOI: 1055-9965.EPI-10-0437]

5 **Dehal AN**, Newton CC, Jacobs EJ, Patel AV, Gapstur SM, Campbell PT. Impact of diabetes mellitus and insulin use on survival after colorectal cancer diagnosis: the Cancer Prevention Study-II Nutrition Cohort. *J Clin Oncol* 2012; **30**: 53-59 [PMID: 22124092]

6 **Chibaudel B**, Tournigand C, André T, de Gramont A. Therapeutic strategy in unresectable metastatic colorectal cancer. *Ther Adv Med Oncol* 2012; **4**: 75-89 [PMID: 22423266 DOI: 10.1177/1758834011431592]

7 **Cunningham D**, Atkin W, Lenz HJ, Lynch HT, Minsky B, Nordlinger B, Starling N. Colorectal cancer. *Lancet* 2010; **375**: 1030-1047 [PMID: 20304247]

8 **Fearon ER**, Vogelstein B. A genetic model for colorectal tumorigenesis. *Cell* 1990; **61**: 759-767 [PMID: 2188735]

9 **Zeki SS**, Graham TA, Wright NA. Stem cells and their implications for colorectal cancer. *Nat Rev Gastroenterol Hepatol* 2011; **8**: 90-100 [PMID: 21293509 DOI: 10.1038/nrgastro.2010.211]

10 **Luebeck EG**, Hazelton WD. Multistage carcinogenesis and radiation. *J Radiol Prot* 2002; **22**: A43-A49 [PMID: 12400946]

11 **Makovski A**, Yaffe E, Shpungin S, Nir U. Down-regulation of Fer induces ROS levels accompanied by ATM and p53 activation in colon carcinoma cells. *Cell Signal* 2012; **24**: 1369-1374 [PMID: 22434045 DOI: 10.1016/j.cellsig.2012.03.004]

12 **Woo DK**, Green PD, Santos JH, D'Souza AD, Walther Z, Martin WD, Christian BE, Chandel NS, Shadel GS. Mitochondrial genome instability and ROS enhance intestinal tumorigenesis in APC(Min/+) mice. *Am J Pathol* 2012; **180**: 24-31 [PMID: 22056359 DOI: 10.1016/j.ajpath.2011.10.003]

13 **Barker N**, Ridgway RA, van Es JH, van de Wetering M, Begthel H, van den Born M, Danenberg E, Clarke AR, Sansom OJ, Clevers H. Crypt stem cells as the cells-of-origin of intestinal cancer. *Nature* 2009; **457**: 608-611 [PMID: 19092804 DOI: 10.1038/nature07602]

14 **Waldner MJ**, Wirtz S, Jefremow A, Warntjen M, Neufert C, Atreya R, Becker C, Weigmann B, Vieth M, Rose-John S, Neurath MF. VEGF receptor signaling links inflammation and tumorigenesis in colitis-associated cancer. *J Exp Med* 2010; **207**: 2855-2868 [PMID: 21098094]

15 **Wong WM**, Mandir N, Goodlad RA, Wong BC, Garcia SB, Lam SK, Wright NA. Histogenesis of human colorectal adenomas and hyperplastic polyps: the role of cell proliferation and crypt fission. *Gut* 2002; **50**: 212-217 [PMID: 11788562 DOI: 10.1136/gut.50.2.212]

16 **Hinoi T**, Akyol A, Theisen BK, Ferguson DO, Greenson JK, Williams BO, Cho KR, Fearon ER. Mouse model of colonic adenoma-carcinoma progression based on somatic Apc inactivation. *Cancer Res* 2007; **67**: 9721-9730 [PMID: 17942902 DOI: 10.1158/0008-5472.CAN-07-2735]

17 **Wong WM**, Garcia SB, Wright NA. Origins and morphogenesis of colorectal neoplasms. *APMIS* 1999; **107**: 535-544 [PMID: 10379680]

18 **Seton-Rogers S**. Microenvironment: Making connections. *Nat Rev Cancer* 2013; **13**: 222-223 [PMID: 23486240 DOI: 10.1038/nrc3492]

19 **Glaire MA**, El-Omar EM, Wang TC, Worthley DL. The mesenchyme in malignancy: a partner in the initiation, progression and dissemination of cancer. *Pharmacol Ther* 2012; **136**: 131-141 [PMID: 22921882 DOI: 10.1016/j.pharmthera.2012.08.007]

20 **Quante M**, Varga J, Wang TC, Greten FR. The gastrointestinal tumor microenvironment. *Gastroenterology* 2013; **145**: 63-78 [PMID: 23583733 DOI: 10.1053/j.gastro.2013.03.052]

21 **Achyut BR**, Bader DA, Robles AI, Wangsa D, Harris CC, Ried T, Yang L. Inflammation-mediated genetic and epigenetic alterations drive cancer development in the neighboring epithelium upon stromal abrogation of TGF-β signaling. *PLoS Genet* 2013; **9**: e1003251 [PMID: 23408900 DOI: 10.1371/journal.pgen.1003251]

22 **Bhowmick NA**, Chytil A, Plieth D, Gorska AE, Dumont N, Shappell S, Washington MK, Neilson EG, Moses HL. TGF-beta signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. *Science* 2004; **303**: 848-851 [PMID: 14764882 DOI: 10.1126/science.1090922]

23 **Franco OE**, Jiang M, Strand DW, Peacock J, Fernandez S, Jackson RS, Revelo MP, Bhowmick NA, Hayward SW. Altered TGF-β signaling in a subpopulation of human stromal cells promotes prostatic carcinogenesis. *Cancer Res* 2011; **71**: 1272-1281 [PMID: 21303979 DOI: 10.1158/0008-5472.CAN-10-3142]

24 **Schwitalla S**, Ziegler PK, Horst D, Becker V, Kerle I, Begus-Nahrmann Y, Lechel A, Rudolph KL, Langer R, Slotta-Huspenina J, Bader FG, Prazeres da Costa O, Neurath MF, Meining A, Kirchner T, Greten FR. Loss of p53 in enterocytes generates an inflammatory microenvironment enabling invasion and lymph node metastasis of carcinogen-induced colorectal tumors. *Cancer Cell* 2013; **23**: 93-106 [PMID: 23273920 DOI: 10.1016/j.ccr.2012.11.014]

25 **Kitamura T**, Kometani K, Hashida H, Matsunaga A, Miyoshi H, Hosogi H, Aoki M, Oshima M, Hattori M, Takabayashi A, Minato N, Taketo MM. SMAD4-deficient intestinal tumors recruit CCR1+ myeloid cells that promote invasion. *Nat Genet* 2007; **39**: 467-475 [PMID: 17369830 DOI: 10.1038/ng1997]

26 **Garcia SB**, Park HS, Novelli M, Wright NA. Field cancerization, clonality, and epithelial stem cells: the spread of mutated clones in epithelial sheets. *J Pathol* 1999; **187**: 61-81 [PMID: 10341707 DOI: 10.1002/(SICI)1096-9896(199901)187: 1<61: : AID-PATH247>3.0.CO; 2-I]

27 **Cohen G**, Mustafi R, Chumsangsri A, Little N, Nathanson J, Cerda S, Jagadeeswaran S, Dougherty U, Joseph L, Hart J, Yerian L, Tretiakova M, Yuan W, Obara P, Khare S, Sinicrope FA, Fichera A, Boss GR, Carroll R, Bissonnette M. Epidermal growth factor receptor signaling is up-regulated in human colonic aberrant crypt foci. *Cancer Res* 2006; **66**: 5656-5664 [PMID: 16740703 DOI: 10.1158/0008-5472.CAN-05-0308]

28 **Tetsu O**, McCormick F. Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. *Nature* 1999; **398**: 422-426 [PMID: 10201372 DOI: 10.1038/18884]

29 **Firestein R**, Bass AJ, Kim SY, Dunn IF, Silver SJ, Guney I, Freed E, Ligon AH, Vena N, Ogino S, Chheda MG, Tamayo P, Finn S, Shrestha Y, Boehm JS, Jain S, Bojarski E, Mermel C, Barretina J, Chan JA, Baselga J, Tabernero J, Root DE, Fuchs CS, Loda M, Shivdasani RA, Meyerson M, Hahn WC. CDK8 is a colorectal cancer oncogene that regulates beta-catenin activity. *Nature* 2008; **455**: 547-551 [PMID: 18794900 DOI: 10.1038/nature07179]

30 **Jones NP**, Schulze A. Targeting cancer metabolism--aiming at a tumour's sweet-spot. *Drug Discov Today* 2012; **17**: 232-241 [PMID: 22207221 DOI: S1359-6446(11)00444-2]

31 **Cairns RA**, Harris IS, Mak TW. Regulation of cancer cell metabolism. *Nat Rev Cancer* 2011; **11**: 85-95 [PMID: 21258394 DOI: 10.1038/nrc2981]

32 **Pouysségur J**, Dayan F, Mazure NM. Hypoxia signalling in cancer and approaches to enforce tumour regression. *Nature* 2006; **441**: 437-443 [PMID: 16724055 DOI: 10.1038/nature04871]

33 **Barrow H**, Rhodes JM, Yu LG. The role of galectins in colorectal cancer progression. *Int J Cancer* 2011; **129**: 1-8 [PMID: 21520033 DOI: 10.1002/ijc.25945]

34 **Waldner MJ**, Neurath MF. The molecular therapy of colorectal cancer. *Mol Aspects Med* 2010; **31**: 171-178 [PMID: 20171980 DOI: 10.1016/j.mam.2010.02.005]

35 **Brahimi-Horn C**, Pouysségur J. The role of the hypoxia-inducible factor in tumor metabolism growth and invasion. *Bull Cancer* 2006; **93**: E73-E80 [PMID: 16935775]

36 **Cardone RA**, Casavola V, Reshkin SJ. The role of disturbed pH dynamics and the Na+/H+ exchanger in metastasis. *Nat Rev Cancer* 2005; **5**: 786-795 [PMID: 16175178 DOI: 10.1038/nrc1713]

37 **Fuller RW**, Perry KW, Molloy BB. Effect of an uptake inhibitor on serotonin metabolism in rat brain: studies with 3-(p-trifluoromethylphenoxy)-N-methyl-3-phenylpropylamine (Lilly 110140). *Life Sci* 1974; **15**: 1161-1171 [PMID: 4550008]

38 **Koh SJ**, Kim JM, Kim IK, Kim N, Jung HC, Song IS, Kim JS. Fluoxetine inhibits NF-κB signaling in intestinal epithelial cells and ameliorates experimental colitis and colitis-associated colon cancer in mice. *Am J Physiol Gastrointest Liver Physiol* 2011; **301**: G9-19 [PMID: 21436313]

39 **Coogan PF**, Palmer JR, Strom BL, Rosenberg L. Use of selective serotonin reuptake inhibitors and the risk of breast cancer. *Am J Epidemiol* 2005; **162**: 835-838 [PMID: 16177141 DOI: 10.1093/aje/kwi301]

40 **Frick LR**, Palumbo ML, Zappia MP, Brocco MA, Cremaschi GA, Genaro AM. Inhibitory effect of fluoxetine on lymphoma growth through the modulation of antitumor T-cell response by serotonin-dependent and independent mechanisms. *Biochem Pharmacol* 2008; **75**: 1817-1826 [PMID: 18342838]

41 **Arimochi H**, Morita K. Characterization of cytotoxic actions of tricyclic antidepressants on human HT29 colon carcinoma cells. *Eur J Pharmacol* 2006; **541**: 17-23 [PMID: 16753142]

42 **Kornhuber J**, Reichel M, Tripal P, Groemer TW, Henkel AW, Mühle C, Gulbins E. The role of ceramide in major depressive disorder. *Eur Arch Psychiatry Clin Neurosci* 2009; **259 Suppl 2**: S199-S204 [PMID: 19876679 DOI: 10.1007/s00406-009-0061-x]

43 **Bertrand PP**, Hu X, Mach J, Bertrand RL. Serotonin (5-HT) release and uptake measured by real-time electrochemical techniques in the rat ileum. *Am J Physiol Gastrointest Liver Physiol* 2008; **295**: G1228-G1236 [PMID: 18927211]

44 **Khanzode SD**, Dakhale GN, Khanzode SS, Saoji A, Palasodkar R. Oxidative damage and major depression: the potential antioxidant action of selective serotonin re-uptake inhibitors. *Redox Rep* 2003; **8**: 365-370 [PMID: 14980069 DOI: 10.1179/135100003225003393]

45 **Zafir A**, Ara A, Banu N. Invivo antioxidant status: a putative target of antidepressant action. *Prog Neuropsychopharmacol Biol Psychiatry* 2009; **33**: 220-228 [PMID: 19059298 DOI: 10.1016/j.pnpbp.2008.11.010]

46 **Zafir A**, Banu N. Antioxidant potential of fluoxetine in comparison to Curcuma longa in restraint-stressed rats. *Eur J Pharmacol* 2007; **572**: 23-31 [PMID: 17610875 DOI: 10.1016/j.ejphar.2007.05.062]

47 **Chung ES**, Chung YC, Bok E, Baik HH, Park ES, Park JY, Yoon SH, Jin BK. Fluoxetine prevents LPS-induced degeneration of nigral dopaminergic neurons by inhibiting microglia-mediated oxidative stress. *Brain Res* 2010; **1363**: 143-150 [PMID: 20858471 DOI: 10.1016/j.brainres.2010.09.049]

48 **Novío S**, Núñez MJ, Amigo G, Freire-Garabal M. Effects of fluoxetine on the oxidative status of peripheral blood leucocytes of restraint-stressed mice. *Basic Clin Pharmacol Toxicol* 2011; **109**: 365-371 [PMID: 21624059 DOI: 10.1111/j.1742-7843.2011.00736.x]

49 **Qi H**, Ma J, Liu YM, Yang L, Peng L, Wang H, Chen HZ. Allostatic tumor-burden induces depression-associated changes in hepatoma-bearing mice. *J Neurooncol* 2009; **94**: 367-372 [PMID: 19381448 DOI: 10.1007/s11060-009-9887-3]

50 **Kirkova M**, Tzvetanova E, Vircheva S, Zamfirova R, Grygier B, Kubera M. Antioxidant activity of fluoxetine: studies in mice melanoma model. *Cell Biochem Funct* 2010; **28**: 497-502 [PMID: 20803706 DOI: 10.1002/cbf.1682]

51 **Kim HJ**, Choi JS, Lee YM, Shim EY, Hong SH, Kim MJ, Min DS, Rhie DJ, Kim MS, Jo YH, Hahn SJ, Yoon SH. Fluoxetine inhibits ATP-induced [Ca(2+)](i) increase in PC12 cells by inhibiting both extracellular Ca(2+) influx and Ca(2+) release from intracellular stores. *Neuropharmacology* 2005; **49**: 265-274 [PMID: 15993448 DOI: 10.1016/j.neuropharm.2005.03.007]

52 **Serafeim A**, Grafton G, Chamba A, Gregory CD, Blakely RD, Bowery NG, Barnes NM, Gordon J. 5-Hydroxytryptamine drives apoptosis in biopsylike Burkitt lymphoma cells: reversal by selective serotonin reuptake inhibitors. *Blood* 2002; **99**: 2545-2553 [PMID: 11895792]

53 **Serafeim A**, Holder MJ, Grafton G, Chamba A, Drayson MT, Luong QT, Bunce CM, Gregory CD, Barnes NM, Gordon J. Selective serotonin reuptake inhibitors directly signal for apoptosis in biopsy-like Burkitt lymphoma cells. *Blood* 2003; **101**: 3212-3219 [PMID: 12515726]

54 **Lee CS**, Kim YJ, Jang ER, Kim W, Myung SC. Fluoxetine induces apoptosis in ovarian carcinoma cell line OVCAR-3 through reactive oxygen species-dependent activation of nuclear factor-kappaB. *Basic Clin Pharmacol Toxicol* 2010; **106**: 446-453 [PMID: 20050848 DOI: 10.1111/j.1742-7843.2009.00509.x]

55 **Levkovitz Y**, Gil-Ad I, Zeldich E, Dayag M, Weizman A. Differential induction of apoptosis by antidepressants in glioma and neuroblastoma cell lines: evidence for p-c-Jun, cytochrome c, and caspase-3 involvement. *J Mol Neurosci* 2005; **27**: 29-42 [PMID: 16055945 DOI: 10.1385/JMN: 27: 1: 029]

56 **Tutton PJ**, Barkla DH. Influence of inhibitors of serotonin uptake on intestinal epithelium and colorectal carcinomas. *Br J Cancer* 1982; **46**: 260-265 [PMID: 6983886]

57 **Brandes LJ**, Arron RJ, Bogdanovic RP, Tong J, Zaborniak CL, Hogg GR, Warrington RC, Fang W, LaBella FS. Stimulation of malignant growth in rodents by antidepressant drugs at clinically relevant doses. *Cancer Res* 1992; **52**: 3796-3800 [PMID: 1617649]

58 **Volpe DA**, Ellison CD, Parchment RE, Grieshaber CK, Faustino PJ. Effects of amitriptyline and fluoxetine upon the in vitro proliferation of tumor cell lines. *J Exp Ther Oncol* 2003; **3**: 169-184 [PMID: 14567288]

59 **Jia L**, Shang YY, Li YY. Effect of antidepressants on body weight, ethology and tumor growth of human pancreatic carcinoma xenografts in nude mice. *World J Gastroenterol* 2008; **14**: 4377-4382 [PMID: 18666329]

60 **Coogan PF**, Strom BL, Rosenberg L. Antidepressant use and colorectal cancer risk. *Pharmacoepidemiol Drug Saf* 2009; **18**: 1111-1114 [PMID: 19623565 DOI: 10.1002/pds.1808]

61 **Chubak J**, Boudreau DM, Rulyak SJ, Mandelson MT. Colorectal cancer risk in relation to antidepressant medication use. *Int J Cancer* 2011; **128**: 227-232 [PMID: 20232382 DOI: 10.1002/ijc.25322]

62 **Lee HK**, Eom CS, Kwon YM, Ahn JS, Kim S, Park SM. Meta-analysis: selective serotonin reuptake inhibitors and colon cancer. *Eur J Gastroenterol Hepatol* 2012; **24**: 1153-1157 [PMID: 22735609 DOI: 10.1097/MEG.0b013e328355e289]

63 **Tutton PJ**, Barkla DH. Serotonin receptors influencing cell proliferation in the jejunal crypt epithelium and in colonic adenocarcinomas. *Anticancer Res* 1986; **6**: 1123-1126 [PMID: 3800319]

64 **Kannen V**, Hintzsche H, Zanette DL, Silva WA, Garcia SB, Waaga-Gasser AM, Stopper H. Antiproliferative effects of fluoxetine on colon cancer cells and in a colonic carcinogen mouse model. *PLoS One* 2012; **7**: e50043 [PMID: 23209640 DOI: 10.1371/journal.pone.0050043]

65 **Kannen V**, Marini T, Turatti A, Carvalho MC, Brandão ML, Jabor VA, Bonato PS, Ferreira FR, Zanette DL, Silva WA, Garcia SB. Fluoxetine induces preventive and complex effects against colon cancer development in epithelial and stromal areas in rats. *Toxicol Lett* 2011; **204**: 134-140 [PMID: 21554931 DOI: 10.1016/j.toxlet.2011.04.024]

66 **Peer D**, Dekel Y, Melikhov D, Margalit R. Fluoxetine inhibits multidrug resistance extrusion pumps and enhances responses to chemotherapy in syngeneic and in human xenograft mouse tumor models. *Cancer Res* 2004; **64**: 7562-7569 [PMID: 15492283]

67 **Argov M**, Kashi R, Peer D, Margalit R. Treatment of resistant human colon cancer xenografts by a fluoxetine-doxorubicin combination enhances therapeutic responses comparable to an aggressive bevacizumab regimen. *Cancer Lett* 2009; **274**: 118-125 [PMID: 18851896 DOI: 10.1016/j.canlet.2008.09.005]

68 **Vandoros GP**, Konstantinopoulos PA, Sotiropoulou-Bonikou G, Kominea A, Papachristou GI, Karamouzis MV, Gkermpesi M, Varakis I, Papavassiliou AG. PPAR-gamma is expressed and NF-kB pathway is activated and correlates positively with COX-2 expression in stromal myofibroblasts surrounding colon adenocarcinomas. *J Cancer Res Clin Oncol* 2006; **132**: 76-84 [PMID: 16215757 DOI: 10.1007/s00432-005-0042-z]

69 **Hardwick JC**, van den Brink GR, Offerhaus GJ, van Deventer SJ, Peppelenbosch MP. NF-kappaB, p38 MAPK and JNK are highly expressed and active in the stroma of human colonic adenomatous polyps. *Oncogene* 2001; **20**: 819-827 [PMID: 11314016 DOI: 10.1038/sj.onc.1204162]

70 **Yang Z**, Li C, Wang X, Zhai C, Yi Z, Wang L, Liu B, Du B, Wu H, Guo X, Liu M, Li D, Luo J. Dauricine induces apoptosis, inhibits proliferation and invasion through inhibiting NF-kappaB signaling pathway in colon cancer cells. *J Cell Physiol* 2010; **225**: 266-275 [PMID: 20509140 DOI: 10.1002/jcp.22261]

71 **Paul S**, DeCastro AJ, Lee HJ, Smolarek AK, So JY, Simi B, Wang CX, Zhou R, Rimando AM, Suh N. Dietary intake of pterostilbene, a constituent of blueberries, inhibits the beta-catenin/p65 downstream signaling pathway and colon carcinogenesis in rats. *Carcinogenesis* 2010; **31**: 1272-1278 [PMID: 20061362 DOI: 10.1093/carcin/bgq004]

72 **Ngan BY**, Forte V, Campisi P. Molecular angiogenic signaling in angiofibromas after embolization: implications for therapy. *Arch Otolaryngol Head Neck Surg* 2008; **134**: 1170-1176 [PMID: 19015446 DOI: 10.1001/archotol.134.11.1170]

73 **Tammali R**, Reddy AB, Srivastava SK, Ramana KV. Inhibition of aldose reductase prevents angiogenesis in vitro and in vivo. *Angiogenesis* 2011; **14**: 209-221 [PMID: 21409599 DOI: 10.1007/s10456-011-9206-4]

74 **Hristov M**, Erl W, Weber PC. Endothelial progenitor cells: mobilization, differentiation, and homing. *Arterioscler Thromb Vasc Biol* 2003; **23**: 1185-1189 [PMID: 12714439 DOI: 10.1161/01.ATV.0000073832.49290.B501.ATV.0000073832.49290.B5]

75 **Sovalat H**, Scrofani M, Eidenschenk A, Pasquet S, Rimelen V, Hénon P. Identification and isolation from either adult human bone marrow or G-CSF-mobilized peripheral blood of CD34(+)/CD133(+)/CXCR4(+)/ Lin(-)CD45(-) cells, featuring morphological, molecular, and phenotypic characteristics of very small embryonic-like (VSEL) stem cells. *Exp Hematol* 2011; **39**: 495-505 [PMID: 21238532 DOI: 10.1016/j.exphem.2011.01.003]

76 **Meregalli M**, Farini A, Belicchi M, Torrente Y. CD133(+) cells isolated from various sources and their role in future clinical perspectives. *Expert Opin Biol Ther* 2010; **10**: 1521-1528 [PMID: 20932225 DOI: 10.1517/14712598.2010.528386]

77 **Li H**, Zimmerlin L, Marra KG, Donnenberg VS, Donnenberg AD, Rubin JP. Adipogenic potential of adipose stem cell subpopulations. *Plast Reconstr Surg* 2011; **128**: 663-672 [PMID: 21572381 DOI: 10.1097/PRS.0b013e318221db33]

78 **Ye C**, Bai L, Yan ZQ, Wang YH, Jiang ZL. Shear stress and vascular smooth muscle cells promote endothelial differentiation of endothelial progenitor cells via activation of Akt. *Clin Biomech (Bristol, Avon)* 2008; **23 Suppl 1**: S118-S124 [PMID: 17928113 DOI: 10.1016/j.clinbiomech.2007.08.018]

79 **Krause DS**, Fackler MJ, Civin CI, May WS. CD34: structure, biology, and clinical utility. *Blood* 1996; **87**: 1-13 [PMID: 8547630]

80 **Beasley NJ**, Wykoff CC, Watson PH, Leek R, Turley H, Gatter K, Pastorek J, Cox GJ, Ratcliffe P, Harris AL. Carbonic anhydrase IX, an endogenous hypoxia marker, expression in head and neck squamous cell carcinoma and its relationship to hypoxia, necrosis, and microvessel density. *Cancer Res* 2001; **61**: 5262-5267 [PMID: 11431368]

81 **Verrax J**, Beck R, Dejeans N, Glorieux C, Sid B, Pedrosa RC, Benites J, Vásquez D, Valderrama JA, Calderon PB. Redox-active quinones and ascorbate: an innovative cancer therapy that exploits the vulnerability of cancer cells to oxidative stress. *Anticancer Agents Med Chem* 2011; **11**: 213-221 [PMID: 21395522]

82 **Schulze A**, Harris AL. How cancer metabolism is tuned for proliferation and vulnerable to disruption. *Nature* 2012; **491**: 364-373 [PMID: 23151579 DOI: 10.1038/nature11706]

83 **Lefebvre M**, Marchand M, Horowitz JM, Torres G. Detection of fluoxetine in brain, blood, liver and hair of rats using gas chromatography-mass spectrometry. *Life Sci* 1999; **64**: 805-811 [PMID: 10075113]

84 **Nagamune H**, Fukushima Y, Takada J, Yoshida K, Unami A, Shimooka T, Terada H. The lipophilic weak base (Z)-5-methyl-2-[2-(1-naphthyl)ethenyl]-4-piperidinopyridine (AU-1421) is a potent protonophore type cationic uncoupler of oxidative phosphorylation in mitochondria. *Biochim Biophys Acta* 1993; **1141**: 231-237 [PMID: 8382953]

85 **Song JH**, Marszalec W, Kai L, Yeh JZ, Narahashi T. Antidepressants inhibit proton currents and tumor necrosis factor-α production in BV2 microglial cells. *Brain Res* 2012; **1435**: 15-23 [PMID: 22177663 DOI: 10.1016/j.brainres.2011.11.041]

86 **Hroudová J**, Fišar Z. In vitro inhibition of mitochondrial respiratory rate by antidepressants. *Toxicol Lett* 2012; **213**: 345-352 [PMID: 22842584 DOI: 10.1016/j.toxlet.2012.07.017]

87 **Hoose SA**, Duran C, Malik I, Eslamfam S, Shasserre SC, Downing SS, Hoover EM, Dowd KE, Smith R, Polymenis M. Systematic analysis of cell cycle effects of common drugs leads to the discovery of a suppressive interaction between gemfibrozil and fluoxetine. *PLoS One* 2012; **7**: e36503 [PMID: 22567160 DOI: 10.1371/journal.pone.0036503]

88 **Eddahibi S**, Fabre V, Boni C, Martres MP, Raffestin B, Hamon M, Adnot S. Induction of serotonin transporter by hypoxia in pulmonary vascular smooth muscle cells. Relationship with the mitogenic action of serotonin. *Circ Res* 1999; **84**: 329-336 [PMID: 10024307]

89 **Pitt BR**, Weng W, Steve AR, Blakely RD, Reynolds I, Davies P. Serotonin increases DNA synthesis in rat proximal and distal pulmonary vascular smooth muscle cells in culture. *Am J Physiol* 1994; **266**: L178-L186 [PMID: 8141313]

90 **Lee SL**, Wang WW, Lanzillo JJ, Fanburg BL. Regulation of serotonin-induced DNA synthesis of bovine pulmonary artery smooth muscle cells. *Am J Physiol* 1994; **266**: L53-L60 [PMID: 8304470]

91 **Krishnan A**, Hariharan R, Nair SA, Pillai MR. Fluoxetine mediates G0/G1 arrest by inducing functional inhibition of cyclin dependent kinase subunit (CKS)1. *Biochem Pharmacol* 2008; **75**: 1924-1934 [PMID: 18371935 DOI: 10.1016/j.bcp.2008.02.013]

92 **Stepulak A**, Rzeski W, Sifringer M, Brocke K, Gratopp A, Kupisz K, Turski L, Ikonomidou C. Fluoxetine inhibits the extracellular signal regulated kinase pathway and suppresses growth of cancer cells. *Cancer Biol Ther* 2008; **7**: 1685-1693 [PMID: 18836303]

93 **Yue CT**, Liu YL. Fluoxetine increases extracellular levels of 3-methoxy-4-hydroxyphenylglycol in cultured COLO320 DM cells. *Cell Biochem Funct* 2005; **23**: 109-114 [PMID: 15565631]

94 **Kashanian S**, Javanmardi S, Chitsazan A, Omidfar K, Paknejad M. DNA-binding studies of fluoxetine antidepressant. *DNA Cell Biol* 2012; **31**: 1349-1355 [PMID: 22510099 DOI: 10.1089/dna.2012.1657]

95 **Peer D**, Margalit R. Fluoxetine and reversal of multidrug resistance. *Cancer Lett* 2006; **237**: 180-187 [PMID: 16014320]

96 **Pavlides S**, Tsirigos A, Vera I, Flomenberg N, Frank PG, Casimiro MC, Wang C, Fortina P, Addya S, Pestell RG, Martinez-Outschoorn UE, Sotgia F, Lisanti MP. Loss of stromal caveolin-1 leads to oxidative stress, mimics hypoxia and drives inflammation in the tumor microenvironment, conferring the "reverse Warburg effect": a transcriptional informatics analysis with validation. *Cell Cycle* 2010; **9**: 2201-2219 [PMID: 20519932]

97 **Martinez-Outschoorn UE**, Pestell RG, Howell A, Tykocinski ML, Nagajyothi F, Machado FS, Tanowitz HB, Sotgia F, Lisanti MP. Energy transfer in "parasitic" cancer metabolism: mitochondria are the powerhouse and Achilles' heel of tumor cells. *Cell Cycle* 2011; **10**: 4208-4216 [PMID: 22033146 DOI: 10.4161/cc.10.24.18487]

98 **Whitaker-Menezes D**, Martinez-Outschoorn UE, Lin Z, Ertel A, Flomenberg N, Witkiewicz AK, Birbe RC, Howell A, Pavlides S, Gandara R, Pestell RG, Sotgia F, Philp NJ, Lisanti MP. Evidence for a stromal-epithelial "lactate shuttle" in human tumors: MCT4 is a marker of oxidative stress in cancer-associated fibroblasts. *Cell Cycle* 2011; **10**: 1772-1783 [PMID: 21558814]

99 **Sotgia F**, Whitaker-Menezes D, Martinez-Outschoorn UE, Flomenberg N, Birbe RC, Witkiewicz AK, Howell A, Philp NJ, Pestell RG, Lisanti MP. Mitochondrial metabolism in cancer metastasis: visualizing tumor cell mitochondria and the "reverse Warburg effect" in positive lymph node tissue. *Cell Cycle* 2012; **11**: 1445-1454 [PMID: 22395432 DOI: 10.4161/cc.19841]

100 **Balliet RM**, Capparelli C, Guido C, Pestell TG, Martinez-Outschoorn UE, Lin Z, Whitaker-Menezes D, Chiavarina B, Pestell RG, Howell A, Sotgia F, Lisanti MP. Mitochondrial oxidative stress in cancer-associated fibroblasts drives lactate production, promoting breast cancer tumor growth: understanding the aging and cancer connection. *Cell Cycle* 2011; **10**: 4065-4073 [PMID: 22129993 DOI: 10.4161/cc.10.23.18254]

101 **Pavlides S**, Whitaker-Menezes D, Castello-Cros R, Flomenberg N, Witkiewicz AK, Frank PG, Casimiro MC, Wang C, Fortina P, Addya S, Pestell RG, Martinez-Outschoorn UE, Sotgia F, Lisanti MP. The reverse Warburg effect: aerobic glycolysis in cancer associated fibroblasts and the tumor stroma. *Cell Cycle* 2009; **8**: 3984-4001 [PMID: 19923890]

**P- Reviewers:** Koukourakis GV, Wang ZH **S- Editor:** Zhai HH **L- Editor: E- Edito**r**:**

**Figure 1 Main metabolic interactions lead to formation of the aerobic glycolytic metabolism in colon tumor cells.** The increased biosynthetic activity of cancer cells, as related to the activation of the aerobic glycolytic metabolism or ‘’Warburg effect’’, is based on the activation of glucose and lactate transporters supplying tumor cells not only with vast amounts of energy (glucose), but further reducing blockage-associated mechanisms due to glycolysis overusing. It seems that the lactate overproduction is compensated by the hyperactivation of lactate transporters allowing a rapid transport of this molecule across the plasma membrane together with H+ atoms, which results in an intracellular alkalinization. This event hyperpolarizes the mitochondrial membrane potential (ΔΨm), and induces a higher uptake of NADH by the first and succinate by the second mitochondrial complexes enhancing the oxidative mitochondrial phosphorylation (Krebs cycle). All together this means that tumor cells are prone to produce higher energy amounts (ATP) than found in a normal tissue.

**Figure 2 Fluoxetine modulates nuclear factor kappa-B nuclear activity among sub-epithelial colonic cells.** For this figure, groups of female C57BL/6 mice (25 g) consisted of control (CTRL) animals or received methylnitronitrosoguanidine (MNNG) treatment (four successive doses of MNNG [5 mg/mL; intrarectal deposits of 100 µL] twice a week for 2 wk), FLX treatment (30 mg/kg per day; intraperitoneal, *ip*) or MNNG+FLX treatment. FLX treatment was started after 2 wk from the end of MNNG treatment, and continued for the next 4-wk. All mice were euthanized by CO2 exposure at week 8. Individual autopsies were performed, and colon tissue samples were fixed in paraformaldehyde buffer (4%; 24 h). All experimental protocols were approved by the Internal Animal Care, Ethical and Use Committee (n° 068/2012). Immunohistochemistry was performed with anti-nuclear factor kappa-light-chain-enhancer of activated B cells [nuclear factor kappa-B (NF-κB) NF-κB, p50; clone C-19], nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor (IκB), alpha (IκB-α; clone N-20), beta (IκB-β; clone H-4). Antibodies were acquired from Santa Cruz Biotechnology (Heidelberg, Germany). A: Representative histological image of a colonic-longitudinal section labeled with anti-NF-κB antibody, picture taken at × 400 magnification, and scale bar of 45 µm inserted. A cytoplasmic anti-NF-κB antibody positively cell detected within cryptal area (inset below;× 1000 magnification of the boxed region, middle-left). Nuclear-NF-κB protein detected in stromal cells (inset right-side;× 1000 magnification of the boxed region, middle-right). Graph shows the relative number of nuclear-NF-κB positive cells within colonic sub-epithelial areas areas (PCCS; b*P* < 0.01 *vs* MNNG without FLX, *n* = 4; FLX+MNNG, *n* = 4); B: Relative number of IκB-α positive cells (a*P* < 0.05 *vs* MNNG without FLX, *n* = 4; FLX+MNNG, *n* = 4); and C: IκB-β positive cells within colon stromal areas (a*P* < 0.05 *vs* MNNG without FLX, *n* = 5; FLX+MNNG, *n* = 4).

**Figure 3 Schematic illustration shows fluoxetine antiproliferative activities in colon tissue.** Boxed figure shows the clear division between epithelial and sub-epithelial colonic areas. Considering that crypts compose the colonic epithelia, it is known that microvessels surround these gland structures. Fluoxetine (chemical structure represented at the center) blocks cell-cycle (blue line and letters) in colonic tissue. We have observed that fluoxetine treatment reduced two proliferative markers, named proliferating cell nuclear antigen (PCNA, red line), and KI67 (green line). These effects of fluoxetine treatment are might related to its enhancement on IκB-α and IκB-β proteins. This could arrest nuclear factor kappa-B (NF-κB) protein in the cytoplasm reducing its transcriptional activity, which, due to its activation over c-Myc transcription factor, would decrease this protein activation and proliferation. We believe that a similar mechanism could take a place in epithelial and sub-epithelial cells.

**Figure 4 Schematic illustration shows fluoxetine anti-angiogenic potential in colon preneoplastic tissue.** This means that reducing proliferation of sub-epithelial cells, blocking their cell-cycle, fluoxetine would reduce microvessel density. This anti-angiogenic potential was observed in a direct relationship with reduced differentiation-related angiogenesis of sub-epithelial stem cells. This suggests that fluoxetine would reduce the differentiation of CD133 positive cells into a CD34 phenotype, which would also not differentiate in endothelial cells, as CD31. This sequence of events would mainly be associated with the control of fluoxetine treatment on nuclear factor kappa-B signaling, as reducing proliferation and preneoplastic angiogenesis.

**Figure 5 Tumor metabolism and malignant angiogenesis.** Histopathological images show double staining between cytochrome C oxidase (COX) and anti-CD31 antibody (clone 1A10 at 1:100; Novocastra, United States). Microvessel walls are traced with sectioned white lines (horizontal view of sectioned tumor microvessels). Black arrow indicates a microvessel lumen with double-stained cells (boxed region; transversal view of a tumor microvessel). Picture was taken at × 100 magnification, and 45 µm scale bars are inserted in all images. Inset (right side, below) shows the same boxed region at x 200 magnification. Double-stained cells are pointed out by a black arrow at the microvessel wall (Inset; left side, below) Sectioned green line circulates a niche of double-stained endothelial cells at the edge of a microvessel bifurcation. To build these images, 5 wk (20 ± 2 g) nonobese diabetic, severe combined immunodeficient mice (NOD/SCID) were subcutaneously transplanted with HT29 cells (1.5 × 106 cells per mice) in agreement with the protocol approved by the Internal Animal Care, Ethical and Use Committee (n° 121/2012). All mice were acclimated for 1 week before starting the experiment, and maintained under specific pathogen-free conditions. Tumor volume was monitored through whole experimental period by measures with a caliper. Mice were sacrificed under general anesthesia (1.5% Forane in 98.5% oxygen; 2l min). Tissue samples were frozen within TissueTek (Sakura, Germany) and kept at -80 ℃ for immunohistochemical analyses. Double-staining was performed according to our standard methods.